Clinical Pharmacology

Go online to PeerView.com/TNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about non-factor therapies in the prophylactic management of hemophilia? Test your knowledge and earn credit, as you get the latest evidence and expert guidance on integrating these therapies into individualized management plans for adult and pediatric patients with hemophilia. Upon completion of this activity, participants should be better able to: Discuss current unmet needs and barriers to optimal prophylaxis of hemophilia; Summarize the MOAs and latest safety/efficacy evidence supporting the use of novel and emerging antibody and siRNA therapies for the prophylaxis of HA and HB; Develop personalized prophylactic regimens with novel and emerging antibody and siRNA therapies, including in the context of clinical trials, for the management of HA and HB; and Manage practical aspects of care when using novel non-factor agents, including dosing/scheduling, patient education, adherence, monitoring, and adverse events.